Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has received approval from China’s National Medical Products Administration to begin clinical trials of FXB0871 for patients with locally advanced or metastatic solid tumours. The company plans to initiate a Phase I study of the candidate in mainland China once trial conditions are met, extending its oncology development footprint.
FXB0871 is an anti-PD-1–targeted IL-2 fusion protein jointly developed with Teva Pharmaceutical Industries, for which Fosun holds exclusive development, manufacturing and commercialisation rights in China and certain Southeast Asian countries. With Teva already running a global Phase I study in the U.S. and Canada, the China trial positions Fosun to leverage international data while strengthening its role in next-generation immuno-oncology therapies and potential future regional market access.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare and pharmaceutical group engaged in the research, development, manufacturing and commercialization of innovative drugs and medical products. Through subsidiaries, it focuses on prescription medicines and biopharmaceuticals, with a growing presence in oncology and collaborations with global partners to expand its pipeline in China and selected overseas markets.
Average Trading Volume: 2,886,175
Technical Sentiment Signal: Sell
Current Market Cap: HK$73.63B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.